GenScript Biotech, the world’s leading life science research tools and services provider, opened a USD 15 million 30,000-square-feet manufacturing facility in Singapore for highly automated protein and gene preparation services. It is the company’s first production facility outside China and United States.
The state-of-the-art site marks a significant expansion of the company’s advanced protein and gene platforms and is designed to provide high-quality, fast-turnaround on products required for new vaccines and therapeutics development and innovations in life sciences. With the support of Singapore’s Economic Development Board (EDB), the new production site will support local scientists to develop new therapeutics, drugs and vaccines. The regional presence will allow GenScript to deliver products more quickly and with higher reliability.
GenScript has played a significant role in Singapore’s research and healthcare sector. During the Covid-19 pandemic, they partnered Duke-NUS and A*Star to develop and manufacture cPass, the world’s first Covid-19 neutralizing antibody test kit with regulatory approval. cPass has been deployed in 64 countries including the US, UK and Germany.
The plant, which currently has 50 staff, is expected to create another 100 jobs for local scientific talent, including laboratory technicians, scientists and logistics personnel.
(Source: The Business Times)